Form 4: Recursion Pharmaceuticals CFO Ben R. Taylor Reports Stock Transactions
SEC Form 4 Filing
Ben R. Taylor, CFO of Recursion Pharmaceuticals, reports acquisition and disposal of Class A Common Stock and stock options.
Summary
- On February 3, 2025, Ben R. Taylor, the Chief Financial Officer of Recursion Pharmaceuticals, reported transactions involving the company's Class A Common Stock and stock options.
- Taylor acquired 35,018 shares of Class A Common Stock at $0 due to vesting of restricted stock units (RSUs) that vest over time.
- He also acquired 13,922 shares of Class A Common Stock at $0 due to immediate vesting of RSUs.
- Taylor disposed of 6,544 shares of Class A Common Stock at $7.25 to cover tax obligations related to the vesting of restricted stock units.
- Following these transactions, Taylor directly owns 886,606 shares of Class A Common Stock.
- Taylor also holds options to buy 70,037 shares at $7.25, which vest monthly starting March 1, 2025, expiring on February 3, 2035.
- He holds other stock options at strike prices of $0.04, $0.06, $0.14 and $6.09.
- The filing was signed by Kyle Nelson, attorney-in-fact, on February 5, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing showing stock transactions by a company executive. The acquisitions through vesting RSUs are mildly positive, while the disposal for tax obligations is neutral.
Positives
- The acquisition of shares through vesting RSUs indicates confidence in the company's future performance.
Negatives
- The disposal of shares to cover tax obligations could be perceived negatively, although it's a common practice.
Risks
- Significant stock ownership by executives could lead to potential conflicts of interest.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. Monitoring these filings can offer insights into management's perspective on the company's valuation and future prospects.
Comparison to Industry Standards
- Executive compensation packages often include stock options and RSUs to align management's interests with those of shareholders.
- The vesting schedules and exercise prices of the options are typical for the industry.
- Comparing Taylor's holdings and transactions to those of executives at similar biotech companies (e.g., Exscientia, Relay Therapeutics) could provide a benchmark for assessing the magnitude of his ownership.
Stakeholder Impact
- Shareholders can use this information to understand the CFO's stake in the company.
- Employees may be interested in the vesting schedules of stock options and RSUs.
Key Dates
| Date | Description |
|---|---|
| 11/17/2021 | 25% of shares subject to $0.04 stock option vest and become exercisable. |
| 04/03/2022 | 25% of shares subject to $0.06 stock option vest and become exercisable. |
| 07/01/2022 | 25% of shares subject to $0.14 stock option vest and become exercisable. |
| 01/02/2025 | 1/48th of the shares subject to the $6.09 stock option vests and become exercisable. |
| 02/03/2025 | Date of the reported transactions involving Class A Common Stock and stock options. |
| 02/03/2025 | Grant date of RSU that vested immediately. |
| 02/03/2025 | Grant date of stock option (Right to Buy) at $7.25. |
| 02/05/2025 | Date the Form 4 was signed by Kyle Nelson, attorney-in-fact. |
| 05/15/2025 | First vesting date for the RSU granted on 02/03/2025. |
| 12/18/2034 | Expiration date for stock option (Right to Buy) at $6.09. |
| 02/03/2035 | Expiration date for stock option (Right to Buy) at $7.25. |
Keywords
Form 4, Recursion Pharmaceuticals, RXRX, Ben R. Taylor, CFO, Stock Options, Class A Common Stock, Beneficial Ownership, Restricted Stock Units, RSU, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.